Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Tablet Ivermectin: Dose: 12 mg
Route: per orally
Frequency:once a day
Duration: for 3 days.
Control Intervention1: Standard of care: standard of care
Sponsors
Dr Rajkumar Nikalje
Eligibility
Inclusion criteria
Inclusion criteria: Symptomatic patients infected with SARS-CoV-2 virus diagnosed on Real time PCR test, admitted to hospital.
Exclusion criteria
Exclusion criteria: 1. Age less than 18 and more 70 years 2. Pregnant and lactating women 3. Patients not willing to give written informed consent 4. Seriously ill patients requiring intensive care 5. Known hypersensitivity to Ivermectin drug 6. Subjects who have participated in another investigational drug or research study within 30 days of screening. 7. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of Ivermectin on eradication of virus by testing for SARS-Co-V-2 by Real time PCR testTimepoint: day 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospitalisationTimepoint: actual number of days of hospitalisation;Reduction in inflammatory markersTimepoint: Day 1, 5, 10;Resolution of signs and symptoms of COVID-19Timepoint: day 3, 5, 10;To assess Safety of ivermectinTimepoint: daily till day 15 | — |
Countries
India
Contacts
Public ContactDr Meenakshi Bhakare
Symbiosis Medical College for Women and symbiosis university hospital and research centre
Outcome results
None listed